Cellect Biotechnology Ltd. – American Depositary Shares (NASDAQ:APOP) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

According to Zacks, “Cellect Biotechnology Ltd. offers biomedical services. It provides stem cell transplantation, disease management, regenerative medicine, clinical research and other services. Cellect Biotechnology Ltd. is based in TEL AVIV, Israel. “

How to Become a New Pot Stock Millionaire

Several other research analysts also recently issued reports on APOP. HC Wainwright set a $14.00 price target on shares of Cellect Biotechnology Ltd. – American Depositary Shares and gave the stock a “buy” rating in a report on Friday, January 5th. ValuEngine downgraded shares of Cellect Biotechnology Ltd. – American Depositary Shares from a “hold” rating to a “sell” rating in a report on Friday, December 1st.

Shares of Cellect Biotechnology Ltd. – American Depositary Shares stock traded down $0.05 during trading hours on Thursday, hitting $7.04. 74,918 shares of the stock traded hands, compared to its average volume of 122,526. The firm has a market capitalization of $38.57, a P/E ratio of -8.59 and a beta of 4.70. Cellect Biotechnology Ltd. – American Depositary Shares has a 52 week low of $6.05 and a 52 week high of $13.50.

A hedge fund recently bought a new stake in Cellect Biotechnology Ltd. – American Depositary Shares stock. Susquehanna International Group LLP acquired a new stake in Cellect Biotechnology Ltd. – American Depositary Shares (NASDAQ:APOP) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,764 shares of the company’s stock, valued at approximately $101,000. Susquehanna International Group LLP owned 0.23% of Cellect Biotechnology Ltd. – American Depositary Shares as of its most recent SEC filing. Hedge funds and other institutional investors own 0.62% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Cellect Biotechnology Ltd. – American Depositary Shares (APOP) Downgraded by Zacks Investment Research” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.watchlistnews.com/cellect-biotechnology-ltd-american-depositary-shares-apop-downgraded-by-zacks-investment-research/1957685.html.

About Cellect Biotechnology Ltd. – American Depositary Shares

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.

Receive News & Ratings for Cellect Biotechnology Ltd. - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology Ltd. - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.